Monoclonal antibodies against IL-1β (Canakinumab) and IL-18 (GSK1070806) are in Phase II trials for severe neutrophilic and Th2-low asthma, respectively, providing a direct strategy to quench the inflammatory output of pyroptosis. Here, IL1B is linked to asthma.